INTRODUCTION: @entity3949 secondary to @entity6 ( @entity6 ) is responsible for @entity2754 ( @entity2754 ) in 5-18% of cases. Medical treatment of @entity2754 is based either on increasing the sympathetic tone of the bladder or on decreasing the parasympathetic activity. However, the onset of side effects and the lack of response should be considered. AIMS: The aim of this study was to analyze long-term outcome of endourethral injection of volume-forming material (VFM) of collagen type 2 into @entity1494 submucosa in @entity1 with @entity2754 secondary to @entity6 . METHODS: Twenty-four @entity1 with complete @entity2754 refractory to @entity2645 and @entity6 were included in the study. @entity1 were single-blinded randomized according to a computer-generated random sequence with a 1:1 ratio in two treatment groups, namely group A (endourethral collage type 2 injection) and group B (endourethral saline water injection). New technique includes an endoscopic injection of VFM such as collagen (Correcting MIT  , Ltd. minimally invasive technologies, Moscow, Russia) into @entity1494 submucosa. Primary endpoint of the study was the reduction of semen antegrade volume (mL). Secondary endpoints were considered as the changes of antegrade count (millions/mL), @entity1319 (%), antegrade progressive motility (%), State-Trait @entity148 Inventory, Beck @entity308 Questionnaire and International Index of Erectile Function (IIEF-5). Pregnancy rate was calculated in each group. RESULTS: Twenty-three @entity1 completed the study. In group A, significant differences from baseline to 12 months were observed relative to antegrade volume (mL) (mean difference: 0.71, P < 0.05), antegrade count (millions/mL) (mean difference: 45.6, P < 0.05), @entity1319 (%) (mean difference: 15.4, P < 0.05) and antegrade progressive motility (%) (mean difference: 8.4, P < 0.05). In group A, we observed significant differences in terms State-Trait @entity148 Inventory (mean difference: -20.5, P < 0.05) and Beck @entity308 Inventory (mean difference: -8.4, P < 0.05) with significant differences compared with group B. We observed significant improvements in group A vs. group B when considering primary and secondary endpoints of the study, but not for the IIEF-5. CONCLUSION: Correction of @entity2754 in @entity6 @entity1 could be achieved with endourethral injection of collagen type 2.

Correction of Retrograde Ejaculation in XXXX with @entity6 Using Endourethral Collagen Injection: Preliminary Results.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder neck'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus type 1', 'DM1'] @entity3949 :: ('MESH:D003929', 'Disease') :: ['Diabetic neuropathy'] @entity148 :: ('MESH:D001008', 'Disease') :: ['Anxiety'] @entity2645 :: ('MESH:D007099', 'Chemical') :: ['imipramine'] @entity2754 :: ('MESH:D061686', 'Disease') :: ['retrograde ejaculation', 'RE'] @entity1319 :: ('MESH:D015835', 'Disease') :: ['antegrade total motility']
@entity1 :: (9606,Species) :: ['Patients']
